Though neurokinin 1 (NK 1 ) receptor antagonists are active in experimental models of depression, clinical efficacy has proven disappointing. This encourages interest in association of NK 1 receptor blockade with inhibition of serotonin (5-HT) reuptake. The selective NK 1 antagonist, GR205171, dose-dependently enhanced citalopram-induced elevations of extracellular levels of 5-HT in frontal cortex, an action expressed stereospecifically vs its less active distomer, GR226206. Further, increases in 5-HT levels in dorsal hippocampus, basolateral amygdala, nucleus accumbens, and striatum were likewise potentiated, and GR205171 similarly facilitated the influence of fluoxetine upon levels of 5-HT, as well as dopamine and noradrenaline. In parallel electrophysiological studies, the inhibitory influence of citalopram and fluoxetine upon raphe-localized serotonergic neurones was stereospecifically blunted by GR205171. Antidepressant actions of citalopram in a forced-swim test in mice were stereospecifically potentiated by GR205171, and it also enhanced attenuation by citalopram of stress-related ultrasonic vocalizations in rats. Further, GR205171 and citalopram additively abrogated the advance in circadian rhythms provoked by exposure to light in hamsters. By contrast, GR205171 stereospecifically blocked anxiogenic actions of citalopram in social interaction procedures in rats and gerbils, and stereospecifically abolished facilitation of fearinduced foot tapping by fluoxetine in gerbils. By analogy to GR205171, a further NK 1 antagonist, RP67580, enhanced the influence of citalopram upon frontocortical levels of 5-HT and potentiated its actions in the forced swim test. In conclusion, NK 1 receptor blockade differentially modulates functional actions of SSRIs: antidepressant properties are reinforced, whereas anxiogenic effects are attenuated. Combined NK 1 receptor antagonism/5-HT reuptake inhibition may offer advantages in the management of depressed and anxious states.
INTRODUCTION
In view of the inadequacies of current treatment of depression, considerable efforts are being made to find improved drugs (Millan, 2004 (Millan, , 2006 Morilak and Frazer, 2004) . In this regard, much attention has been devoted to NK 1 receptors which transduce the actions of substance P (Rupniak et al, 2001; Holmes et al, 2003) . Several preclinical and clinical observations support the utility of NK 1 receptor blockade in the control of depressedFand anxiousFstates. First, long-term treatment with various classes of antidepressant modifies central tissue levels of substance P, an effect observed in the absence of an alteration in NK 1 receptor expression (Shirayama et al, 1996; Sartori et al, 2004) . Second, NK 1 receptors are localized in: the dorsal raphe nucleus (DRN), the origin of ascending serotonergic projections (Froger et al, 2001; Santarelli et al, 2001; Commons and Valentino, 2002; Ma and Bleasdale, 2002; Lacoste et al, 2006) ; the locus coeruleus, the source of adrenergic input to corticolimbic regions (Santarelli et al, 2001; Ma and Bleasdale, 2002) ; and the ventrotegmental area (VTA), from which dopaminergic pathways project to the frontal cortex (FCX) and limbic regions (Lessard and Pickel, 2005) . Third, NK 1 receptors are broadly distributed in limbic structures implicated in the control of mood, such as the FCX, hippocampus, lateral septum, nucleus accumbens, basolateral amygdala (BLA), and hypothalamus (Liu et al, 2002; Saffroy et al, 2003) . Fourth, substance P exerts aversive effects in rodents, whereas mice genetically deprived of NK 1 receptors reveal improved resistance to stress and display an anxiolytic phenotype (Rupniak et al, 2001; Santarelli et al, 2001) . Fifth, selective NK 1 receptor antagonists exert antidepressant and anxiolytic actions in several, though not all, experimental models (Rupniak et al, 2001; Varty et al, 2002; Dableh et al, 2005; Renoldi and Invernizzi, 2006) , and they attenuate the behavioral response to stress (Ebner et al, 2004) .
The above observations prompted clinical evaluation of several selective NK 1 receptor antagonists, including MK869 (aprepitant) and L759274, which revealed beneficial effects in major depression with improved tolerance (less sexual dysfunction) as compared to SSRIs (Kramer et al, 1998 (Kramer et al, , 2004 Gerald et al, 2006) . Nonetheless, therapeutic trials of NK 1 antagonists have not overall yielded convincing evidence of robust and reproducible antidepressant actions, tempering enthusiasm for their further development. This has triggered interest in the concept of combining NK 1 antagonist properties with suppression of 5-HT reuptake, either as drug associations or in a single chemical structure (Ryckmans et al, 2002; Guiard et al, 2004; Millan, 2006) . Such agents would be expected to exert complementary antidepressant properties, potentially with greater efficacy and rapidity of action than SSRIs and selective NK 1 blockers, respectively. Support for this notion has been generated by both neurochemical and electrophysiological studies in rodents. Thus, the influence of SSRIs upon extracellular levels of 5-HT in FCX was reinforced in mice genetically lacking NK 1 receptors, possibly due to desensitization of feedback actions at inhibitory 5-HT 1A autoreceptors in the DRN (Froger et al, 2001; Santarelli et al, 2001; Guiard et al, 2005; Gobbi et al, 2007) . By analogy, Guiard et al (2004) demonstrated that the effect of paroxetine on frontocortical 5-HT levels in mice were potentiated by the NK 1 antagonists, GR205171 and L733060.
These elegant studies underpin the notion that NK 1 receptor blockade may enhance the influence of SSRIs upon serotonergic transmission, but several important issues and questions remain to be addressed. First, neurochemical studies of the influence of NK 1 antagonists on the actions of SSRIs have to date been restricted to mice, and it would be desirable to reproduce such findings in other species. Second, the influence of NK 1 receptor blockade upon SSRIelicited increases in 5-HT levels has been evaluated in the FCX, but it would be interesting to extend such work to other corticolimbic structures implicated in depressed states, like the hippocampus, BLA, nucleus accumbens, and striatum. Third, certain 'SSRIs' also enhance extracellular levels of noradrenaline (NA) and dopamine (DA) in FCX , but it has not been determined whether NK 1 receptor antagonists likewise modify the influence of SSRIs upon dopaminergic and adrenergic transmission. Fourth, subactive doses of SSRIs exert antidepressant actions in the mouse forced swim (FS) test in the presence of GR205171 . Remarkably, however, no other data on how NK 1 antagonists may modify the behavioral actions of SSRIs are available. In this light, it would be of particular interest to examine whether the acute anxiogenic actions of SSRIs (Dekeyne et al, 2000) are modified by blockade of NK 1 receptors.
The present studies addressed these questions employing combined neurochemical, electrophysiological, and behavioral approaches, together with the highly selective NK 1 receptor antagonist, GR205171. In contrast to most agents, GR205171 possesses high affinity at NK 1 receptors across a broad range of species, though its affinity is higher for NK 1 receptors in gerbils and guinea pigs (which closely resemble those in humans) than rats and mice (Rupniak et al, 2000; Griffante et al, 2006; Engberg et al, 2007) . GR205171 was also chosen in view of its well-characterized actions in vivo (Gardner et al, 1996; Millan et al, 2001b; Lejeune et al, 2002; Guiard et al, 2004; Chenu et al, 2006) , and as clinical studies have shown that it relieves social phobia (Furmark et al, 2005; Michelgard et al, 2007) . To underpin the stereospecificity of the actions of GR205171, its effects were compared to those of its less active distomer, GR226206 (op. cit.).
MATERIALS AND METHODS

Animals
Unless specified below, these studies employed male Wistar rats (225-250 g body weight upon arrival) and male CD mice (22-26 g upon arrival) supplied by Charles River (L'Arbresle and Saint Aubin les Elbeuf, France, respectively). Male Mongolian gerbils (50-70 g upon arrival) were acquired from CERJ (Le Genest, St-Isle, France). Male Syrian hamsters (70-80 g upon arrival) were obtained from Charles River Laboratories (Kingston, NY, USA). Rats, mice, and gerbils were housed in standard Macrolon, sawdustlined cages and hamsters were housed in polycarbonate cages lined with sterilized pine chips and unrestricted access to food and water. Except for hamsters (see below), there was a light/dark cycle with lights on from 07 : 30 to 19 : 30 hours. All animal use procedures conformed to international European ethical standards (86/609-EEC) and the French National Committee (décret 87/848) for the care of laboratory animals. Hamster use was approved by the Institutional Animal Care and Use Committee of Valdosta State University and complied with regulations outlined in the US Animal Welfare Act.
Cerebral Microdialysis and Chromatographic Procedures
The protocol used for quantification of levels of 5-HT, DA, and NA in dialysate samples was detailed elsewhere (Millan et al, 2001b) . Briefly, a guide-cannula was implanted under pentobarbital anesthesia (60 mg/kg, i.p.) into the FCX, nucleus accumbens, striatum, or dorsal hippocampus of rats as previously described (Millan et al, 2001b) . For the BLA, coordinates were AP, 2.8; ML, ±4.9; and DV, 6.4 from dura. Experiments were performed 5 days later after placement of the guide cannula following placement of a cuprophane CMA/11 probe: 0.24 mm in diameter, 4 mm in length for FCX and striatum, and 2 mm for the dorsal hippocampus, BLA and nucleus accumbens. Samples were taken every 20 min over 1 h, then GR205171 or vehicle was injected i.p. followed, 20 min later, by s.c. administration of citalopram, fluoxetine, 8-OH-DPAT or S15535. In further experiments, injection of citalopram was preceded by treatment with GR226206 or RP67580. Sampling was pursued for a further 3 h. Monoamine levels were quantified as described previously (above citations) by HPLC and electrochemical detection.
Electrophysiological Procedure
As detailed previously (Lejeune et al, 2002) , rats were anaesthetized with chloral hydrate (400 mg/kg, i.p.) and, after cannulation of the femoral vein, placed in a stereotaxic apparatus. A tungsten microelectrode was slowly lowered into the DRN (from bregma and the sinus surface, AP, 7.2; ML, ± 0.0; and DV, 5.5/6.5). After amplification (CP511; Grass Technology, USA) and A/D conversion (micro1401-mkII; CED, Cambridge, UK) of electrical activity, data were recorded using Spike2 software (CED). Serotonergic neurones were identified by their waveform and spontaneous firing patterns (E1.2 Hz). One cell was recorded per animal. The spontaneous firing rate was recorded for 5 min before i.v. administration of vehicle, GR205171, or GR226206. After 3 min, the influence of citalopram, fluoxetine, 8-OH-DPAT, S15535, (À)-pindolol, or buspirone, injected i.v. in volumes of 0.5 ml/kg, was evaluated upon administration in cumulative doses at intervals of 2-3 min. Drug effects were characterized over 60 s periods at the time of peak action.
Forced Swim Test in Mice
As previously described (Brocco et al, 2006) , mice were placed in individual glass cylinders (24 cm h Â 12 cm diameter) containing 6 cm of water at 251C for 6 min. Immobility (s) was measured during the last 4 min of the test. In dose-range studies of citalopram (s.c.) and GR205171 (i.p.), drug or vehicle was administered 30 min before testing. In antagonist studies, GR205171, GR226206, RP67580, or vehicle was administered (i.p.) 30 min before treatment with citalopram (2.5 mg/kg, s.c.) or vehicle, and testing undertaken 30 min later.
Influence Upon Locomotor Activity in Mice
As described (Brocco et al, 2002) , locomotor activity in mice was evaluated using white Plexiglass cages (27 Â 27 Â 27 cm) equipped with two rows of four photocells 2 cm above the floor and 6 cm apart connected through an interface to a microcomputer (Hesperid, Loiron, France). GR205171 or vehicle (i.p.), then citalopram or vehicle (s.c.), was administered 60 and 30 min before placing mice in individual activity chambers for 10 min. Each interruption of an infrared beam was counted as a movement.
Ultrasonic Vocalization Test in Rats
As previously (Millan et al, 2001a) , rats were initially placed in a chamber equipped with a grid floor and were exposed to six randomly distributed, electric shocks (800 mA, 8 s) over a 7 min period. After 24 h, they were placed in the chamber for 2 min and received a single shock. They were returned to the chamber 30 min later and the total duration of ultrasonic vocalizations (USVs), defined as vocalizations with frequencies higher than 20 kHz, were recorded as previously (Millan et al, 1997a) over 10-min by use of a microphone linked to an ultrasound recording system (Ultravox; Noldus, Wageningen, The Netherlands). Rats emitting USVs for less than 90 s were not examined further. After 24 h, the procedure was replicated following drug administration. GR205171, GR226206, citalopram or vehicle was administered immediately after the 2 min session and, in potentiation studies, animals received GR205171, GR226206 or vehicle, followed by citalopram or vehicle, immediately after the 2 min session.
Fear-Induced Foot Tapping in Gerbils
As previously (Brocco et al, 2008) , the procedure involved two sessions: (1) acquisition of fear conditioning followed, 4 h later, by (2) a test session. The apparatus was a chamber with a floor comprised of four metal plates (10 Â 4 cm) connected to a shocker (Apelex, Massy, France). In the acquisition session, naive gerbils were placed for 2 min habituation in the chamber, then a shock was (1.75 mA, 0.5 s) delivered manually each time the animal crossed from one plate to another. Each animal received 10 shocks, separated by at least 10 s intervals without shock. For testing, the animal was placed again in the four-plate chamber for 3 min and the duration (s) of foot-tapping bouts recorded. No shock was delivered during the test session. GR205171, GR226206, or vehicle was administered i.p. together with either vehicle or fluoxetine (40.0 mg/kg, i.p.), 30 min before the test session.
Social Interaction Tests in Rats and Gerbils
As previously (Millan et al, 2001a; Brocco et al, 2008) , male Sprague-Dawley rats of 240-260 g (Charles River, SaintAubin-les-Elbeuf, France) or gerbils were maintained under a 12/12 h low light (3 lux)/dark cycle for 5 days before testing, and individually housed 5 days (rats) or 3 h (gerbils) before testing. On the test day, they were placed in weight-matched pairs ( ± 5 g for rats and ± 3 g for gerbils) in opposite corners of a highly illuminated (300 lux) open-topped arena for a 10 (rats) or 5 min (gerbils) observation session. Data were the duration of active SI: ie, the time spent in grooming, following, sniffing, biting, jumping, or crawling over or under the other animal. If animals remained adjacent to each other without any movement for more than 10 s, scoring was discontinued until active SI resumed. Both animals of the same pair receive the same drug treatment. GR205171, citalopram, or vehicle was administered 30 min before testing. In interaction studies, GR205171, GR226206, or vehicle was administered 45 min before testing, and citalopram or vehicle 30 min before testing.
Light-Induced Phase-Advances in Circadian Wheel Running Rhythms in Hamsters
As previously (Gannon and Millan, 2007) , Syrian hamsters were maintained in a 14 : 10 h light : dark schedule for several weeks before being transferred to conditions of constant darkness (DD) where they had access to small running wheels of 19 cm in diameter. Wheel running was recorded in 10 min bins using Actimetrics ClockLab hardware (Evanstown, IL, USA). Food and water was provided ad libitum at all times. Onset of wheel running in DD is defined as circadian time (CT 12). Data were recorded for approximately 10 days in DD and then hamsters were removed from their home cages under dim red light (o1 lux) at circadian time 18.25, weighed, and injected with either drug or vehicle and returned to their home cage. After 45 min at CT, 19 hamsters were again removed from their home cage and exposed to a 10-min pulse of white light (20 lux) and then returned to their home cage for another 10 days. Hamsters were returned to the 14 : 10 h lighting schedule at the conclusion of the experiment. Light pulses delivered at CT 19 to hamsters in DD phase advance the time of onset of wheel running. The magnitude of the phase advance was determined by fitting a line through the activity onset for several days before the light pulse and again for several days after the light pulse once the rhythm has stabilized, normally days 5-10 after light. The difference in time between the two fitted lines on the day of the experiment indicates the magnitude of the light-induced phase advance.
Drugs and Sources
Drug doses are expressed in terms of the base. Drugs were dissolved in distilled water and administered s.c., i.p., or i.v. (electrophysiology). For i.p. administration, drugs were administered as suspensions in water with a few drops of Tween 80. GR205171 (2-methoxy-5-(5-trifluoromethyltetra-
pram HBr, RP67580 ((3aR,7aR)-imino-1(methoxy-2-phenyl)-2-diphenyl-7,7-perhydro isoindolone-4), and S15535 (1-(1,4-benzodioxan-5-yl)-4-(indan-2-yl) piperazine mesylate) were synthetized by Servier chemists. 8-OH-DPAT (8-dihydroxy-2(di-n-propylamino)tetralin) HBr, (À)-pindolol, 635 (N-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N-(2-pyridyl)cyclohexane carboxamide) maleate and buspirone were purchased from Sigma-RBI (Natick, USA). Fluoxetine HCl was purchased from Interchim (Montluçon, France).
RESULTS
Enhancement by GR205171 of the Influence of Citalopram and Fluoxetine Upon Dialysis Levels of 5-HT in Frontal Cortex of Freely Moving Rats
At a dose of 0.63 mg/kg, s.c., citalopram markedly increased levels of 5-HT in the FCX of freely moving rats ( Figure 1 ; Table 1 ). In contrast, levels of DA and NA were not modified. In an opposite fashion, the selective NK 1 antagonist, GR205171 (10.0-40.0 mg/kg, s.c.), had no effect on frontocortical levels of 5-HT, whereas it elevated levels of DA and NA. This effect of GR205171 was expressed stereospecifically in that its less active distomer, GR226206 ( Figure 1 Enhancement by the neurokinin (NK) 1 receptor antagonist, GR205171, of the influence of citalopram upon dialysis levels of serotonin in frontal cortex of freely-moving rats. Serotonin (5-HT), dopamine (DA), and noradrenaline (NA) levels are expressed relative to basal values defined as 100%. These were 0.96 ± 0.06, 1.12 ± 0.07, and 1.84 ± 0.08 pg per 20 ml for 5-HT, DA, and NA respectively. Data are means ± SEMs; N ¼ 5-9 per value. Arrows denote the injection of drugs. For ANOVA with dose as between factor, see legend to Table 1 . 
Enhancement by GR205171 of the Influence of Citalopram Upon Dialysis Levels of 5-HT in Diverse Cerebral Structures of Freely Moving Rats
In the dorsal hippocampus, BLA, nucleus accumbens, and striatum, at a dose of 0.63 mg/kg, s.c., citalopram increased levels of 5-HT ( Figure 2 ; Table 2 ). It also slightly elevated the levels of DA and NA in the BLA. By contrast, it did not affect NA (dorsal hippocampus) or DA (nucleus accumbens and striatum). GR205171 (40.0 mg/kg, s.c.), did not affect 5-HT levels in any structure. It did not modify DA levels in nucleus accumbens, and slightly decreased DA levels in striatum. However, it enhanced levels of DA in the BLA and those of NA in BLA and dorsal hippocampus. In the presence of GR205171, the influence of citalopram upon 5-HT was potentiated, but changes in DA and NA were not modified.
Attenuation by GR205171 of the Inhibitory Influence of Citalopram and Fluoxetine Upon the Firing Rate of Serotonergic Neurones
Citalopram suppressed the electrical activity of DRNlocalized serotonergic neurones ( Figure 3 ). Administered alone, GR205171 failed to modify firing rate. However, it dose-dependently (1.0-4.0 mg/kg, i.v.) and significantly displaced the dose-response curve for inhibition of serotonergic neurones by citalopram to the right. The effects of citalopram alone and of citalopram in the presence of GR205171 were both blocked by the selective 5-HT 1A receptor antagonist, WAY100635 (0.1 mg/kg, i.v.) (Newman-Tancredi et al, 1998). In distinction to GR205171, 
Influence of GR205171 Upon Inhibition of Serotonergic Neurones by 5-HT 1A Agonists
The 5-HT 1A partial agonist, S15535 (Gobert et al, 1995; Millan et al, 1997a, b; Lejeune and Millan, 2000) , dose dependently reduced the firing rate of DRN neurones (Figure 4 ). Its dose-response curve was shifted to the right by GR205171 (4.0 mg/kg, i.v.). This effect was expressed stereospecifically in that GR226206 (4.0 mg/kg, i.v.) failed to influence the decrease in DRN firing rate induced by S15535. In contrast, GR205171 (4.0) did not modify the inhibitory influence of the weak 5-HT 1A partial agonist, (À)-pindolol (Newman-Tancredi et al, 1998), nor of the 5-HT 1A agonists, 8-OH-DPAT and buspirone (Gobert et al, 1995; Lejeune et al, 1997; Newman-Tancredi et al, 1998) , upon DRN firing rate. Actions of all 5-HT 1A agents were antagonized by WAY100635 (0.1 mg/kg, i.v.).
Influence of GR205171 Upon the Modulation of FCX Levels of Monoamines By 5-HT 1A Agonists S15535 decreased levels of 5-HT in the FCX of freelymoving rats, and increased levels of DA and NA ( Figure 5 ).
The inhibitory influence of S15535 upon 5-HT levels was not affected by GR205171. Interestingly, coadministration of GR205171 and S15535 was accompanied by a more pronounced elevation in levels of DA and NA than for either drug alone. 8-OH-DPAT also decreased 5-HT levels in FCX while increasing the levels of DA and NA. In the presence of GR205171, the reduction in 5-HT levels provoked by 8-OH-DPAT was unaffected, whereas the elevation in DA and NA was facilitated.
Enhancement by GR205171 of the Antidepressant Action of Citalopram in the Forced Swim Procedure in Mice
In the mice FS test, citalopram decreased the duration of immobility, whereas GR205171 had no effect up to 40.0 mg/ kg, i.p. (Figure 6 ). In the presence of GR205171 (40.0), however, a subactive dose of citalopram (2.5) significantly decreased immobility. This effect was not observed with GR226206 ( 
Lack of Enhancement by GR205171 of the Facilitatory Influence of Citalopram Upon Locomotor Activity in Mice
Citalopram (10.0 mg/kg, s.c.) increased locomotor activity in mice (Table 3) . This action was dose-dependently (2.5-40.0 mg/kg, i.p.) attenuated by GR205171. Locomotor activity was not significantly modified by GR205171 alone. 
Additive Inhibition by GR205171 and Citalopram of Light-Induced Phase Advances in Circadian Wheel Running Rhythms in Hamsters
A 10-min light pulse advanced circadian rhythms by 1.6 ± 0.1 h following vehicle (Table 4) . Citalopram (5 mg/ kg, i.p.) and GR205171 (5.0 mg/kg, i.p) alone did not influence light-induced phase advances. In contrast, combination of these doses significantly inhibited the effect of light (À47%). Further, citalopram (10.0 mg/kg) and GR205171 (20.0 mg/kg) significantly inhibited the effect of light by À40 and À70%, respectively. When injected simultaneously, the combination inhibited the effect of light by 60%.
Blockade by GR205171 of the Facilitation by Fluoxetine of Fear-Induced Foot-Tapping in Gerbils
In animals without fear conditioning (ie not submitted to shocks during the acquisition session), fluoxetine (40.0 mg/ kg, i.p.) did not induce foot tapping (Figure 8 ). In contrast, in fear-conditioned gerbils (submitted to shocks), fluoxetine dose-dependently induced foot tapping at doses of 20.0 and 40.0 mg/kg, i.p. The dose of 40.0 mg/kg, i.p. was selected for antagonist studies. GR205171 (0.16 mg/kg, i.p.) blocked the effect of fluoxetine (40.0 mg/kg, i.p.) upon fear-conditioned foot tapping whereas GR226206 was inactive.
Blockade by GR205171 of the Anxiogenic Actions of Citalopram in the Social Interaction Test in Rats and Gerbils
Citalopram reduced the duration of SI between unfamiliar rats and gerbils exposed to a novel environment (Figure 9 ). 
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In contrast, GR205171 alone did not modify the duration of SI in either species. However, GR205171 (10.0 mg/kg, i.p. in rat, and 0.63 in gerbils) antagonized the anxiogenic effect of citalopram. Conversely, GR226206 was inactive.
Influence of RP67580 Upon Neurochemical and Antidepressant Actions of Citalopram
The 
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Figure 5 Influence of GR205171 upon the modulation of frontocortical levels of monoamines by the 5-HT 1A agonists, S15535 and 8-OH-DPAT, in freely moving rats. Serotonin (5-HT), dopamine (DA), and noradrenaline (NA) levels are expressed relative to basal values defined as 100% (see legend of Figure 1 ). Data are means ± SEMs; N ¼ 5-9 per value. Arrows denote the injection of drugs. ANOVA as follows. S15535, 5-HT: S15535, F(1, 11) ¼ 50. 
DISCUSSION
Potentiation by GR205171 of the Influence of Citalopram Upon 5-HT Levels
Several arguments underpin the specificity of the facilitation by GR205171 of increases in levels of 5-HT elicited by citalopram in FCX. First, GR205171 is a highly selective antagonist of NK 1 receptors and expressed its actions across a dose range identical to that exerting other cerebral actions in rodents (Gardner et al, 1996; Millan et al, 2001b; Rupniak et al, 2001; Lejeune et al, 2002; Brocco et al, 2008) . Further, its actions were stereospecific in as much as its less active isomer, GR226206, was ineffective. Second, the influence of GR205171 was reproduced with another selective NK 1 antagonist, RP67580 (Garret et al, 1991; Gobbi et al, 2007) , and GR205171 also stereospecifically augmented the influence of fluoxetine upon 5-HT levels in FCX. Third, GR205171 potentiates paroxetine-induced increases in extracellular levels of 5-HT in the FCX of mice (Guiard et al, 2004) . Fourth, herein, GR205171 also enhanced the action of citalopram in four further structures receiving serotonergic input from the DRN and controlling affect (Millan, 2003 (Millan, , 2006 : hippocampus, BLA, nucleus accumbens, and striatum. Fifth, the enhancement of SSRI-induced increases in FCX levels of 5-HT by GR205171 was paralleled by its suppression of their inhibition of DRN-localized serotonergic neurones. Finally, pharmacokinetic interactions are unlikely to be involved as: (1) two different NK 1 antagonists facilitated the neurochemical effects of two different SSRIs; (2) compatible findings were acquired in electrophysiological studies using the i.v. route, a route which avoids first pass elimination in the liver; (3) certain responses to SSRIs were blocked by NK 1 antagonists; (4) similar results were seen in mice using paroxetine , and (5) genetic deletion of NK 1 receptors likewise enhances the influence of SSRIs upon levels of 5-HT (Guiard et al, 2004 (Guiard et al, , 2005 .
Integration at the Level of the DRN: Significance of 5-HT 1A Autoreceptors .5) for 5-HT transporters (pK i values, o5.0), and do not modify the actions of SSRIs at synaptosomes in vitro (Lieb et al, 2005; Millan, MJ, unpublished observation) . Antagonists at 5-HT 1B autoreceptors on serotonergic terminals enhances increases in 5-HT levels elicited by SSRIs (Gobert et al, 1997) . However, GR205171 and RP67580 have no affinity for 5-HT 1B receptors, and this would not explain their abrogation of the inhibitory influence of SSRIs on serotonergic neurones in the DRN (Gardner et al, 1996; Millan et al, 2000) . Rather, inhibitory 5-HT 1A autoreceptors are localized on serotonergic perikarya, and 5-HT 1A antagonists likewise enhance increases in FCX levels of 5-HT elicited by SSRIs (Gobert et al, 1997; Millan et al, 2000; Guilloux et al, 2006) . Though GR205171 and RP67580 do not behave as 5-HT 1A antagonists (pK i values, o5.0; Gardner et al, 1996; Figure 5 ), it is important to consider the significance of 5-HT 1A autoreceptors.
In agreement with most studies of NK 1 antagonists Conley et al, 2002; Lejeune et al, 2002; Guiard et al, 2005; Gobbi et al, 2007) , GR205171 did not affect the spontaneous activity of DRN-localized serotonergic neurones. However, its reduction of the inhibitory influence of citalopram and fluoxetine upon DRN firing mimics the effects of chronic administration of NK 1 antagonists (Haddjeri and Blier, 2001; Guiard et al, 2005) , and of genetic elimination of NK 1 receptors in mice (Froger et al, 2001; Santarelli et al, 2001; Gobbi et al, 2007) . A subpopulation (some 30%) of 5-HT neurones in the DRN bear NK 1 receptors (Froger et al, 2001; Ma and Bleasdale, 2002; Lacoste et al, 2006) , raising the possibility that NK 1 antagonists (via signalling crosstalk) disrupt the inhibitory influence of SSRI-engaged 5-HT 1A autoreceptors upon DRN firing. Indeed, the inhibitory influence of 5-HT 1A agonists on the DRN is blunted by chronic treatment with NK 1 antagonists (Haddjeri and Blier, 2001; Guiard et al, 2005) , and by genetic deletion of NK 1 receptors (Froger et al, 2001; Santarelli et al, 2001) . However, acute blockade of NK 1 receptors does not generally desensitize 5-HT 1A autoreceptors (Blier et al, 2004; Guiard et al, 2007; Gobbi et al, 2007) , and GR205171 did not modify the influence of 5-HT 1A agonists on DRN firing rate in vitro (Guiard et al, 2005) . Correspondingly, the lack of influence of GR205171 upon the inhibition of DRN firing (Figure 4 ) by two 5-HT 1A agonists, 8-OH-DPAT and buspirone (Lejeune et al, 1997) , suggests that it does not markedly affect the sensitivity of 5-HT 1A autoreceptors. Conversely, GR205171 attenuated the inhibitory influence of a lower efficacy (ca 30-40% vs 5-HT) 5-HT 1A ligand, S15535 (Millan et al, 1997a, b; NewmanTancredi et al, 1998) upon DRN firing. Thus, this partial agonist may reveal a subtle alteration by NK 1 receptor blockade of coupling at 5-HT 1A autoreceptors. However, changes in firing rate do not invariably translate into alterations in release (Gobert et al, 1995; Millan and Gobert, 1999; Millan et al, 2000; Artigas et al, 2001; Gobbi et al, 2007) , and the reduction by S15535 (and 8-OH-DPAT) of 5-HT release in FCX was not modified by GR205171. Moreover, GR205171 did not modify the influence on serotonergic neurones of (À)-pindolol, a low efficacy 5-HT 1A ligand (ca 20%) which only submaximally decreases firing rate (Newman-Tancredi et al, 1998; Millan and Gobert, 1999; Guilloux et al, 2006) . Recruitment of postsynaptic 5-HT 1A receptors in FCX triggers long-loop, inhibitory feedback to serotonergic cell bodies in raphe nuclei Celada et al, 2001; Sharp et al, 2007) . However, they are unlikely to be involved in the activations of GR205171 as the sensitivity of postsynaptic 5-HT 1A receptors is unaffected by NK 1 antagonists (Froger et al, 2001; Haddjeri and Blier, 2001; Santarelli et al, 2001) . Further, though microinjection of substance P into the FCX suppressed 5-HT release, this action did not involve frontocortical 5-HT 1A receptors (Guiard et al, 2007) .
Possible Involvement of Gabaergic, Glutatamergic, and Adrenergic Mechanisms NK 1 receptors have been identified on GABAergic neurones surrounding 5-HT cell bodies in the DRN, and studies in the septum and cortex suggest that NK 1 receptor antagonists may indirectly excite serotonergic neurones via a reduction of inhibitory GABAergic tone (Sloviter et al, 2001; Ma and Bleasdale, 2002; Stacey et al, 2002; Szeidemann et al, 1995; Ebner et al, 2008) . This would enhance their responsiveness to SSRIs, by analogy to GABA B antagonists (Millan, 2006; Cremers et al, 2007) . Glutamatergic terminals targeting serotonergic DRN neurones also bear NK 1 receptors (Liu et al, 2002; Valentino et al, 2003) , and their stimulation by intraraphe perfusion of substance P enhances local release of 5-HT via recruitment of AMPA receptors (Guiard et al, 2007) . This results in a (delayed) decrease in cortical 5-HT release due to activation of 5-HT 1A autoreceptors. That is, in line with the present observations, NK 1 receptors are 'upstream' of 5-HT 1A autoreceptors. Interestingly, by analogy to lateral septum (Ebner et al, 2008) , frontocortical perfusion of substance P suppressed local release of 5-HT in mice, an effect blocked by GR205171 and absent in mice lacking NK 1 receptors (Guiard et al, 2007) . Thus, NK 1 antagonists conceivably also enhance SSRI-induced increase in 5-HT levels by actions in the FCX and other structures innervated by the DRN. Finally, Gobbi et al (2007) found that functionally intact adrenergic terminals are essential for the facilitatory influence of NK 1 receptor antagonists upon DRN firing. This is coherent with the excitatory impact of NK 1 receptor blockade upon electrical activity of LC-derived adrenergic neurones (Millan et al, 2001b; Gobbi et al, 2007) .
Influence of NK 1 Receptor Blockade Upon NA and DA Levels
Elevations in levels of NA in FCX are seen in mice genetically deprived of NK 1 receptors and are elicited by NK 1 antagonists in parallel with an excitation of the LC (Millan et al, 2001b; Maubach et al, 2002; Blier et al, 2004; Ebner and Singewald, 2007; Gobbi et al, 2007) . Correspondingly, GR205171 and RP67580 increased extracellular levels of NA in FCX, as well as in the BLA and hippocampusFstructures likewise innervated by the LC (Millan et al, 2001b) . The VTA possess a high density of NK 1 sites (Lessard and Pickel, 2005) , and electrical activity of VTAlocalized dopaminergic neurons is accelerated by blockade of NK 1 receptors, an effect accompanied by increases in DA levels in FCX (Lejeune et al, 2002) . This finding was confirmed herein for GR205171, reproduced with RP67580 and extended to the BLA. Interestingly, neither agent affected DA levels in striatum or nucleus accumbens which are innervated by different subpopulations of dopaminergic cell bodies: that is, substantia nigra pars compacta (nigrostriatal) and paranigral-VTA (mesolimbic) vs parabrachial-VTA (mesocortical), respectively (Lejeune et al, 1997; Lejeune and Millan, 2000) . These observations accord with the differential control of these clusters of dopaminergic neurons Adell and Artigas, 2004; Alex and Pehek, 2007) , including 5-HT 1A receptor agonism which disinhibits VTA-derived mesocortical dopaminergic and LC-derived adrenergic pathways via GABAergic interneurones Invernizzi et al, 2007) . Interestingly, 8-OH-DPAT and S15535-induced elevations in FCX levels of DA and NA (Millan et al, 1997b; Gobert et al, 1995 Gobert et al, , 1999 , were additive to those of GR205171. This indicates that 5-HT 1A agonism and NK 1 receptor blockade offer complementary strategies for improvement of affect (Lucki et al, 1994; Millan, 2003 Millan, , 2006 Czeh et al, 2006) . GR205171 and fluoxetine likewise additively augmented dialysate levels of NA and DA in FCX, suggesting complementary mood-elevating properties independent of 5-HT . Accordingly, association of NK 1 receptor blockade with high doses of SSRIs, with the NA reuptake inhibitor, reboxetine, or with 5-HT/NA reuptake inhibitors like venlafaxine (Morilak and Frazer, 2004; Millan, 2006) , may lead to more pronounced elevations in NA levels in FCX and improved antidepressant efficacy.
Enhancement of the Effects of Citalopram in a Forced Swim Procedure
Addition of GR205171 to a subactive dose of citalopram led to a significant antidepressant effect, an action exerted stereoselectively vs GR226206. These observations support the finding of a recent study of GR205171 and paroxetine by Chenu et al (2006) Fthough stereospecificity was not demonstrated. Apart from the hippocampus, the septum is implicated in antidepressant actions of SSRIs (Sheehan et al, 2004; Millan, 2006) , and NK 1 antagonists may enhance 5-HT release in this region via inhibition of GABAergic interneurons (Szeidemann et al, 1995; Millan, 2006; Ebner et al, 2008) . As GR205171 blunted the increase in locomotor activity elicited by citalopram herein (Table 3) , potentiation of the actions of citalopram in the FS procedure is unlikely to reflect stimulation of motor behavior (Redrobe and Bourin, 1998; Brocco et al, 2006) . Likewise, augmentation of paroxetine-induced decreases in immobility in the FS test occurred at a dose of GR205171 which did not increase its motor actions .
Enhancement of the Action of Citalopram in the Stress-Related Ultrasonic Vocalization Test
Exposure of rats to stress elicits USVs at a characteristic frequency of 22 kHz (De Vry et al, 1993; Sánchez, 2003) . This model is sensitive to SSRIs and, accordingly, citalopram reduced USVs (Molewijk et al, 1996; Sanchez and Meier, 1997; Millan et al, 2001a; Sánchez, 2003) . Curiously, actions of NK 1 antagonists have not, as yet been documented. In fact, periaqueductal grey administration of substance P reduced USVs elicited by isolation in rats (Bassi et al, 2007) , but NK 1 antagonists suppress isolation-induced (nonultrasonic) vocalizations in juveniles via actions in the amygdala (Molewijk et al, 1996; Rupniak et al, 2000; Brocco et al, 2008) . This observation is coherent with the present finding that GR205171 attenuates stress-induced USVs. Moreover, though the difference in potency between GR205171 and GR226206 was, for unclear reasons, less marked in this procedure than for other paradigms, only GR205171 potentiated the inhibitory influence of citalopram on USVs. These data suggest that NK 1 receptor blockade may enhance the abrogation of stress-elicited behaviors by SSRIs.
Additive Influence on Circadian Rhythms
A normalization of perturbed diurnal scheduling of behavior is implicated in the therapeutic actions of certain antidepressants (Duncan, 1996; Millan, 2006) . Light-induced phase shifts of activity rhythms in hamsters are blunted by several classes of antidepressant, including SSRIs (Millan, 2006; Gannon and Millan 2007) . They likely act in the suprachiasmatic nucleus, which contains a high density of 5-HT transporters on serotonergic terminals originating in the median raphe nucleus (Legutko and Gannon, 2001) . Intriguingly, a similar suppression of lightinduced circadian phase-shifts is seen with NK 1 antagonists, which act upstream in the raphe to intensify serotonergic input to the suprachiasmatic nucleus (Valentino et al, 2003; Gannon and Millan, 2005) . Consistent with contrasting mechanisms of action, subthreshold doses of citalopram and GR205171 additively prevented light-triggered phaseshifts. Accordingly, combined NK 1 receptor blockade and suppression of 5-HT reuptake may mutually restore circadian rhythmicity in certain depressed patients.
Blockade of the Anxiogenic Effects of Citalopram and Fluoxetine
SSRIs elicits anxiogenic effects in the SI procedure in rats, an observation extended herein to gerbils (Dekeyne et al, 2000; Millan, 2003) . By contrast, NK 1 receptor antagonists either fail to affect, or enhance, SI, probably dependent upon the degree of substance P release (File, 1997; Dekeyne et al, 2000; Varty et al, 2002; Millan, 2003; Brocco et al, 2008; Ebner et al, 2008) . GR205171 stereospecifically abolished the reduction in SI elicited by citalopram in rats, and similar results were acquired in gerbils, a species in which NK 1 receptors are potently blocked by GR205171 (Griffante et al, 2006; Engberg et al, 2007) . Serotonin 2C receptors in the hippocampus, amygdala and/or locus coeruleus mediate anxiogenic actions of SSRIs (Dekeyne et al, 2000; Millan 2003; Campbell and Merchant, 2003; Salchner and Singewald, 2006) . However, GR205171 does not affect the reduction in SI provoked by 5-HT 2C agonists (Dekeyne A, unpub. obs.) , suggesting an action 'upstream' of 5-HT 2C sites. These observations are supported by a further paradigm based on enhancement of fear-conditioned anxiety by SSRIs. Association of a mild aversive stimulus with fluoxetine triggers a characteristic foot-thumping response in gerbils (Millan, 2003; Rupniak et al, 2003; Burghardt et al, 2007; Brocco et al, 2008) . By analogy to other NK 1 antagonists (op. cit.), this behavior was stereospecifically abrogated by GR205171, supporting the contention that acute anxiogenic effects of SSRIs are tempered by NK 1 receptor blockade. SSRI-induced nervousness reduces compliance, triggers early abandonment of therapy and is associated with a long delay to efficacy (Millan, 2003 (Millan, , 2006 Morilak and Frazer, 2004 ). The present observations suggest that NK 1 receptor antagonists, which show anxiolytic properties in patients with major depression or social phobia (Kramer et al, 1998 (Kramer et al, , 2004 Michelgard et al, 2007) , may alleviate anxiogenic effects of SSRIs at the onset of therapy.
General Discussion
First, the present data show that the antidepressant efficacy of SSRIs is enhanced by blockade of NK 1 receptors, yet that their acute anxiogenic actions are abrogated. Thus, the present observation support the association of SSRIs and selective NK 1 antagonists and the development of mixed NK 1 antagonists/5-HT reuptake inhibitors for treatment of depression and anxiety (Ryckmans et al, 2002; Chenu et al, 2006; Millan, 2006; Brocco et al, 2008) . Second, association of GR205171 with fluoxetine led to additive increases in levels of NA and DA suggesting that interactions between NK 1 antagonists and antidepressants may also involve dopaminergic and adrenergic mechanisms. GR205171 did not potentiate antidepressant actions of the NA reuptake inhibitor, desipramine , and desipramine did not more markedly increase NA levels in NK 1 knock-out mice . Nonetheless, it would be of interest to examine the influence of GR205171 upon actions of mixed 5-HT/NA reuptake inhibitors like venlafaxine, and the atypical agent, mirtazapine Morilak and Frazer, 2004; Millan, 2006) . This argument is underpinned by the marked elevation in FCX levels of DA and NA elicited by GR205171 together with 8-OH-DPAT or S15535, 5-HT 1A receptor agonists possessing antidepressant and anxiolytic properties (Lucki et al, 1994; Millan et al, 1997a, b; Millan, 2006) . Third, NK 2 and NK 3 receptors influence mood and modulate monoaminergic pathways, possibly in interaction with NK 1 receptors (Steinberg et al, 2001; Bert et al, 2002; Léger et al, 2002; Spooren et al, 2005) . Accordingly, it would be interesting to examine how blockade of NK 2 and NK 3 receptors affects the functional actions of antidepressants.
CONCLUSIONS
The present observations strongly suggest that combining NK 1 receptor blockade with suppression of 5-HT reuptake may yield benefits in the treatment of anxious and depressed states relative to selective NK 1 antagonists and SSRIs.
